PMID- 37933122
OWN - NLM
STAT- MEDLINE
DCOM- 20231108
LR  - 20231114
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Print)
IS  - 1479-1641 (Linking)
VI  - 20
IP  - 6
DP  - 2023 Nov-Dec
TI  - Optimizing statin therapy for primary prevention of cardiovascular disease in 
      type 2 diabetes mellitus patients: Exploring dose, class, and intensity.
PG  - 14791641231214507
LID - 10.1177/14791641231214507 [doi]
LID - 14791641231214507
AB  - PURPOSE: To investigate the impact of statin use on primary prevention of 
      cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) in 
      a dose-, class-, and use intensity-dependent manner. METHODS: We used an inverse 
      probability treatment-weighted Cox hazards model, with statin use status as a 
      time-dependent variable. RESULTS: Our results showed that statin use was 
      associated with a significant reduction in CVD risk with an adjusted hazard ratio 
      of 0.39. Pitavastatin was found to have the lowest CVD risk among the different 
      classes of statins, followed by rosuvastatin, pravastatin, atorvastatin, 
      simvastatin, fluvastatin, and lovastatin. Our analysis also revealed that a 
      higher cumulative defined daily dose per year of statin was associated with a 
      lower CVD risk. Additionally, a higher intensity of daily statin dose was 
      associated with a lower CVD risk in patients with T2DM. CONCLUSION: This study 
      highlights the importance of statin use in reducing the risk of CVD in patients 
      with T2DM, and the significance of dose, class, and intensity of statin use, in 
      particular, pitavastatin class of statins was found to be the most effective in 
      primary prevention of CVD in T2DM.
FAU - Yu, Jung-Min
AU  - Yu JM
AD  - Department of Cardiovascular Surgery, Taichung Tzu Chi Hospital, Taichung, 
      Taiwan.
AD  - Department of Surgery, School of Medicine, Tzu Chi University, Hualien, Taiwan.
FAU - Chen, Wan-Ming
AU  - Chen WM
AD  - Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, Taipei, Taiwan.
AD  - Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, 
      Taiwan.
FAU - Shia, Ben-Chang
AU  - Shia BC
AUID- ORCID: 0000-0003-2854-8361
AD  - Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, Taipei, Taiwan.
AD  - Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, 
      Taiwan.
FAU - Wu, Szu-Yuan
AU  - Wu SY
AUID- ORCID: 0000-0001-5637-558X
AD  - Graduate Institute of Business Administration, College of Management, Fu Jen 
      Catholic University, Taipei, Taiwan.
AD  - Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, 
      Taiwan.
AD  - Department of Food Nutrition and Health Biotechnology, College of Medical and 
      Health Science, Asia University, Taichung, Taiwan.
AD  - Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai 
      Hospital, Yilan, Taiwan.
AD  - Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, 
      Taiwan.
AD  - Department of Healthcare Administration, College of Medical and Health Science, 
      Asia University, Taichung, Taiwan.
AD  - Cancer Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
AD  - Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang 
      Hospital, Taipei Medical University, Taipei, Taiwan.
AD  - Department of Management, College of Management, Fo Guang University, Yilan, 
      Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research
JID - 101234011
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
SB  - IM
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Rosuvastatin Calcium/therapeutic use
MH  - Primary Prevention
PMC - PMC10631324
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - cardiovascular disease
OT  - class of statin
OT  - dose-dependent
OT  - primary prevention
OT  - statin
COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/11/07 06:46
MHDA- 2023/11/08 06:41
PMCR- 2023/11/06
CRDT- 2023/11/07 03:38
PHST- 2023/11/08 06:41 [medline]
PHST- 2023/11/07 06:46 [pubmed]
PHST- 2023/11/07 03:38 [entrez]
PHST- 2023/11/06 00:00 [pmc-release]
AID - 10.1177_14791641231214507 [pii]
AID - 10.1177/14791641231214507 [doi]
PST - ppublish
SO  - Diab Vasc Dis Res. 2023 Nov-Dec;20(6):14791641231214507. doi: 
      10.1177/14791641231214507.